News | Cardiac Diagnostics | December 14, 2015

Mount Sinai Initiates Clinical Study of MyoVista Heart Screening Device

Clinical study will evaluate new technology from Heart Test Laboratories as possible low-cost screening tool for early heart disease

Heart Test Laboratories, HTL, MyoVista Heart Screening Device, clinical study, Mount Sinai

December 14, 2015 — Heart Test Laboratories Inc. (HTL) announced the commencement of a clinical study, initiated by Mount Sinai Medical Center, New York, examining the MyoVista heart screening device. The clinical study is designed to further evaluate the MyoVista, which incorporates HTL’s patented technology for the early detection of heart disease. The study will assess the MyoVista indications for the identification of coronary arterial disease (CAD) as compared to computed tomographic coronary angiography (CTA) and myocardial dysfunction in patients without CAD as compared to echocardiography.

The lead investigator is Partho Sengupta, M.D., the director of cardiac ultrasound research and core lab, and an associate professor of medicine in cardiology at Mount Sinai’s Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health. The clinical study is expected to enroll 200 patients and take between 12-24 months to complete.

Heart disease is the leading cause of death in the U.S., being responsible for 1 in every 4 deaths (approx. 600,000 per year U.S.). It is the leading cause of deaths worldwide, more than all cancers combined, and is the largest spend area in healthcare. Heart disease is known as the silent killer because most affected people do not know they have it (i.e. they are asymptomatic); more than half of patients find out through an adverse event (angina, heart attack or even death).

The “diagnostic gap” in heart disease today is non-invasive, low-cost screening to identify asymptomatic patients before an adverse event occurs. Existing electrocardiography (ECG) technology is generally not considered effective for use on asymptomatic patients. The U.S. Preventive Services Taskforce and other healthcare bodies around the world recommend against screening with resting or exercise ECG for the prediction of coronary heart disease (CHD) events in asymptomatic adults at low risk for CHD events.

The MyoVista provides two tests in one and is easy for physicians to use. By using standard 12-lead resting ECG protocols, the device provides an ECG test incorporating interpretive analysis, as well as easy-to-understand proprietary informatics that assist a physician in identifying heart disease at an early stage.

HTL believes the MyoVista will provide the opportunity for effective, low-cost testing for heart disease in primary care. This would enable physicians to have a valuable additional tool to assist in the process of determining referrals to a cardiologist.

It has a 15.6-inch high resolution touch screen and incorporates user features and functionality commonly associated with a tablet device which make it intuitive and easy to use, thereby reducing training time. Its proprietary informatics provide information to physicians that suggest ischemic and certain types of structural heart abnormalities. The MyoVista is ideally suited for use in both primary care and hospital environments.

For more information:

Related Content

Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
Overlay Init